Motzer RJ - Search Results

1

PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine.

Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. Herati RS, et al. Among authors: motzer rj. Nat Immunol. 2022 Aug;23(8):1183-1192. doi: 10.1038/s41590-022-01274-3. Epub 2022 Jul 28. Nat Immunol. 2022. PMID: 35902637 Free PMC article.

2

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ. Motzer RJ, et al. Semin Oncol. 1992 Dec;19(6 Suppl 12):8-11. Semin Oncol. 1992. PMID: 1336624

3

Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

Bajorin DF, Herr H, Motzer RJ, Bosl GJ. Bajorin DF, et al. Among authors: motzer rj. Semin Oncol. 1992 Apr;19(2):148-58. Semin Oncol. 1992. PMID: 1372757 Review.

4

"Poor-risk" germ cell tumors: current progress and future directions.

Motzer RJ, Bajorin DF, Bosl GJ. Motzer RJ, et al. Semin Oncol. 1992 Apr;19(2):206-14. Semin Oncol. 1992. PMID: 1372761 Review. No abstract available.

5

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

6

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ. Motzer R, et al. Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598. Invest New Drugs. 1990. PMID: 2084073 Clinical Trial.

7

Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.

Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Mencel PJ, et al. Among authors: motzer rj. J Clin Oncol. 1994 Jan;12(1):120-6. doi: 10.1200/JCO.1994.12.1.120. J Clin Oncol. 1994. PMID: 7505805

8

Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy.

Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Murphy BA, et al. Among authors: motzer rj. Cancer. 1994 May 15;73(10):2520-6. doi: 10.1002/1097-0142(19940515)73:10<2520::aid-cncr2820731012>3.0.co;2-r. Cancer. 1994. PMID: 7513603

9

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.

Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P. Motzer RJ, et al. J Clin Oncol. 1994 Nov;12(11):2277-83. doi: 10.1200/JCO.1994.12.11.2277. J Clin Oncol. 1994. PMID: 7525885 Clinical Trial.

10

Germ cell tumors.

Bajorin DF, Motzer RJ, Bosl GJ. Bajorin DF, et al. Among authors: motzer rj. Curr Ther Endocrinol Metab. 1994;5:354-9. Curr Ther Endocrinol Metab. 1994. PMID: 7535661 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

600 results

Search Page